These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 21971209

  • 1. Adiponectin and leptin serum levels in osteoporotic postmenopausal women treated with raloxifene or alendronate.
    Sebastián-Ochoa A, Fernández-García D, Reyes-García R, Mezquita-Raya P, Rozas-Moreno P, Alonso-Garcia G, Muñoz-Torres M.
    Menopause; 2012 Feb; 19(2):172-7. PubMed ID: 21971209
    [Abstract] [Full Text] [Related]

  • 2. Relationships between serum adiponectin, leptin concentrations and bone mineral density, and bone biochemical markers in Chinese women.
    Wu N, Wang QP, Li H, Wu XP, Sun ZQ, Luo XH.
    Clin Chim Acta; 2010 May 02; 411(9-10):771-5. PubMed ID: 20184866
    [Abstract] [Full Text] [Related]

  • 3. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
    Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, Verbruggen N, Melton ME.
    J Intern Med; 2004 Apr 02; 255(4):503-11. PubMed ID: 15049885
    [Abstract] [Full Text] [Related]

  • 4. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harper K.
    Chin Med J (Engl); 2004 Jul 02; 117(7):1029-35. PubMed ID: 15265377
    [Abstract] [Full Text] [Related]

  • 5. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R, Muñoz-Torres M, García DF, Mezquita-Raya P, García Salcedo JA, de Dios Luna J.
    Menopause; 2010 Jul 02; 17(1):140-4. PubMed ID: 19574937
    [Abstract] [Full Text] [Related]

  • 6. Serum leptin levels and body composition in postmenopausal women treated with tibolone and raloxifene.
    Tommaselli GA, Di Carlo C, Di Spiezio Sardo A, Bifulco G, Cirillo D, Guida M, Capasso R, Nappi C.
    Menopause; 2006 Jul 02; 13(4):660-8. PubMed ID: 16837888
    [Abstract] [Full Text] [Related]

  • 7. The effect of raloxifene on cardiac autonomic regulation in osteoporotic women.
    Gol M, Baris N, Guneri S, Posaci C.
    Am J Obstet Gynecol; 2006 May 02; 194(5):1249-54. PubMed ID: 16647907
    [Abstract] [Full Text] [Related]

  • 8. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate.
    Muñoz-Torres M, Reyes-García R, Mezquita-Raya P, Fernández-García D, Alonso G, Luna Jde D, Ruiz-Requena ME, Escobar-Jiménez F.
    Maturitas; 2009 Nov 20; 64(3):188-92. PubMed ID: 19819089
    [Abstract] [Full Text] [Related]

  • 9. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    J Bone Miner Metab; 2005 Nov 20; 23(3):238-42. PubMed ID: 15838627
    [Abstract] [Full Text] [Related]

  • 10. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis.
    Michalská D, Stepan JJ, Basson BR, Pavo I.
    J Clin Endocrinol Metab; 2006 Mar 20; 91(3):870-7. PubMed ID: 16352692
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May 20; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 13. [Prediction of changes in bone density during alendronate treatment in postmenopausal women].
    Masaryk P, Stancíková M, Letkovská A, Rovenský J.
    Vnitr Lek; 2002 Oct 20; 48(10):943-7. PubMed ID: 16737141
    [Abstract] [Full Text] [Related]

  • 14. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, DeLucca P, Melton M.
    Curr Med Res Opin; 2007 Jun 20; 23(6):1341-9. PubMed ID: 17594775
    [Abstract] [Full Text] [Related]

  • 15. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z.
    Eur Cytokine Netw; 2007 Sep 20; 18(3):148-53. PubMed ID: 17823083
    [Abstract] [Full Text] [Related]

  • 16. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harpe K.
    Zhonghua Yi Xue Za Zhi; 2004 Feb 17; 84(4):269-73. PubMed ID: 15059505
    [Abstract] [Full Text] [Related]

  • 17. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.
    Nephrol Dial Transplant; 2009 May 17; 24(5):1472-7. PubMed ID: 19075192
    [Abstract] [Full Text] [Related]

  • 18. Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
    Zikan V, Stepan JJ.
    Bone; 2009 Apr 17; 44(4):634-8. PubMed ID: 19150421
    [Abstract] [Full Text] [Related]

  • 19. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL, He JW, Qin YJ, Huang QR, Liu YJ, Hu YQ, Li M.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr 17; 23(2):129-33. PubMed ID: 16604479
    [Abstract] [Full Text] [Related]

  • 20. The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.
    Yanik B, Bavbek N, Yanik T, Inegöl I, Kanbay M, Turgut FH, Uz E, Akçay A.
    Ren Fail; 2007 Apr 17; 29(4):471-6. PubMed ID: 17497471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.